Although many studies have uncovered an important role for the receptor-binding protein kinase RIP1 in controlling cell death signaling, its possible contributions to cancer pathogenesis have been little explored. Here, we report that RIP1 functions as an oncogenic driver in human melanoma. Although RIP1 was commonly upregulated in melanoma, RIP1 silencing inhibited melanoma cell proliferation in vitro and retarded the growth of melanoma xenografts in vivo. Conversely, while inducing apoptosis in a small proportion of melanoma cells, RIP1 overexpression enhanced proliferation in the remaining cells. Mechanistic investigations revealed that the proliferative effects of RIP1 overexpression were mediated by NF-kB activation. Strikingly, ectopic expression of RIP1 enhanced the proliferation of primary melanocytes, triggering their anchorageindependent cell growth in an NF-kB-dependent manner. We identified DNA copy-number gain and constitutive ubiquitination by a TNFa autocrine loop mechanism as two mechanisms of RIP1 upregulation in human melanomas. Collectively, our findings define RIP1 as an oncogenic driver in melanoma, with potential implications for targeting its NF-kB-dependent activation mechanism as a novel approach to treat this disease. Cancer Res; 75(8); 1736-48. Ó2015 AACR.
Introduction
Aberrant activation of survival signaling pathways plays an important role in cancer development, progression, and resistance to treatment (1) . In melanoma, identification of activating mutations in BRAF as the major cause of constitutive activation of the MAPK pathway has led to successful development of mutant BRAF-specific inhibitors in the treatment of the disease (2) . However, primary and acquired resistance, which is commonly associated with activation of other survival pathways, remains a major obstacle in the quest for curative treatment (3, 4) .
Receptor-interacting protein kinase 1 (RIP1) mediates both cell survival and death signaling and is emerging as an important determinant of cell fate in response to cellular stress, in particular, to activation of death receptors such as TNFa receptor 1 (TNFaR1; refs. [5] [6] [7] [8] . Upon TNFaR1 stimulation, RIP1, along with other proteins, including TRADD, TRAF2, cIAP1, and cIAP2, is recruited to form prosurvival complex I (5, 9, 10) . This results in stabilization of RIP1 through K63-linked poly-ubiquitination and/or linear ubiquitination of the protein carried out by TRAF2/cIAPs and linear ubiquitin chain assembly complex (LUBAC), respectively (8, (11) (12) (13) . K63 polyubiquitin and linear ubiquitin chains linked to RIP1 serve as substrates for binding of the TAB2/TAB3/TAK1 complex and NEMO, leading to activation of NF-kB, which plays an important role in regulating many cellular processes (11, 12) .
The expression of cIAPs is regulated by second mitochondriaderived activator of caspases (Smac), which is released from mitochondria upon activation of mitochondrial apoptotic signaling (14) . Once in the cytosol, Smac binds to cIAPs, leading to their degradation (14) . A number of small-molecule chemicals that function pharmacologically as Smac mimetic have been shown to similarly cause cIAP degradation (15, 16) . When cIAPs are inhibited, RIP1 is deubiquitinated by the ubiquitin-editing enzyme A20 and the deubiquitinase cylindromatosis (17, 18) . This switches the function of RIP1 to that of promoting apoptosis in complex IIa containing FADD and caspase-8 upon exposure to TNFa (6, 8) . In this case, the kinase activity of RIP1 is essential for TNFa-induced apoptosis (8) . However, if caspase-8 activation is limited, RIP1 recruits RIP3, leading to formation of complex IIb causing programmed necrosis (necroptosis) in some types of cells (6, 9) . Noticeably, TNFa can also trigger apoptosis independently of RIP1 when protein synthesis is inhibited (19, 20) . This induction of apoptosis is inhibitable by cFLIP, but is not affected by inhibition of RIP1 kinase activity (21) .
Many studies in recent years have primarily focused on the role of RIP1 in induction of cell death (5) (6) (7) . In particular, the role of RIP1 in apoptosis and necrosis of various types of cancer cells in response to therapeutic agents is being increasingly reported (6, 7) . However, RIP1 À/À mice display extensive apoptosis in selected tissues and die at age 1 to 3 days (5) , indicating that RIP1 has an important role in cell survival in a tissue type-specific manner. Indeed, recent evidence suggests that RIP1 is constitutively polyubiquitinated by cIAPs and interacts with TAK to facilitate cell survival in a number of cancer cell lines (9, 22) . Nonetheless, little is known about the role of RIP1 in the pathogenesis of melanoma.
In this study, we have examined the role of RIP1 in the development and progression of melanoma. We report here that RIP1 is commonly upregulated and plays a role in melanoma cell proliferation through activation of NF-kB. Moreover, we show that although overexpression of RIP1 causes anchorage-independent growth of melanocytes, knockdown of RIP1 retards melanoma growth in a xenograft model. Our results also reveal that autocrine TNFa contributes to upregulation of RIP1 through IAPmediated K63-linked polyubiquitination, and that RIP1 in turn protects against TNFa-induced apoptosis in melanoma cells.
Materials and Methods

Cell lines and human tissues
Human melanoma cell lines described previously were cultured in DMEM containing 5% FCS (23) . Human melanocytes (HEMa-LP, HEMn-DP, and HEMn-MP) were purchased from Banksia Scientific and cultured as previously described (24) . Human fresh melanoma isolates were prepared from surgical specimens according to the published method (25) . Individual cell line authentication was confirmed using the AmpFISTR Identifiler PCR Amplification Kit from Applied Biosystems and GeneMarker V1.91 software (SoftGenetics LLC). A panel of 16 markers was tested, and each cell line had a distinct individual set of markers present (26) . Tissue microarrays were constructed from formalin-fixed paraffin-embedded (FFPE) melanocytic tumour tissues retrieved from the Department of Tissue Pathology and Diagnostic Oncology at the Royal Prince Alfred Hospital, Australia ( Supplementary Table S1 ). Studies using human tissues were approved by the Human Research Ethics Committees of the University of Newcastle and Royal Prince Alfred Hospital, Australia.
Antibodies and reagents
The antibody against RIP1 used in immunoprecipitation and antibodies against cIAP1, cIAP2, TNFaR1, and NEMO were purchased from Santa Cruz Biotechnology. The antibody against RIP1 used in Western blotting was from BD Biosciences. Antibodies against phospho-IkBa, IkBa, and cFLIP were from Cell Signaling Technology. The antibody against K63-linked ubiquitin was from Novus Biologicals. The blocking antibody against TNFa and recombinant human TNFa was from R&D Systems. The RIP1 kinase inhibitor necrostatin-1 (Nec-1), the Smac mimetic SM406, and the caspase inhibitor z-VAD-fmk were from Selleckchem. The NF-kB inhibitors PDTC and BAY-11-7082 were from Sigma-Aldrich. The NF-kB reporter assay Kit was from QIAGEN.
IHC
IHC staining and quantitation were performed as described previously (27) . Briefly, antigen retrieval was performed in a pressure cooker for 30 seconds at 125 C. Antibody detection was performed using the Dako Envision HRP Detection system/DAB as per the manufacturer's instructions. Slides were counterstained with Azure B to differentiate the melanin from the brown DAB immunolabeling.
Cell viability
A CellTiter-Glo Luminescent Cell Viability Assay kit was used according to the manufacturer's instructions (Promega). Cells were seeded at 5 Â 10 3 /well in 96-well plates overnight before treatment as desired. CellTiter-Glo Reagent (100 mL) was added and incubated for 10 minutes. Luminescence was recorded by Synergy 2 multidetection microplate reader (BioTek; ref. 28 ).
Clonogenic assays
Cells were seeded at 2,000/well onto 6-well plates and allowed to grow for 24 hours followed by the desired treatment. Cells were -GAPDH then allowed to grow for a further 12 days before fixation with methanol and staining with crystal violet (0.5% solution).
Cell proliferation assays
BrdUrd cell proliferation assays were carried out using an assay kit (Cell Signaling Technology) as per the manufacturer's instructions. Briefly, cells were seeded at 5 Â 10 3 /well in 96-well plates overnight before treatment as desired. BrdUrd (10 mmol/L) was added and cells were incubated for 4 hours before BrdUrd assays were carried out. Absorbance was read at 450 nm using a Synergy 2 multidetection microplate reader (BioTek).
NF-kB reporter assays
NF-kB activity assays were performed using an assay kit (Qiagen) as per the manufacturer's instructions (29) . Briefly, cells transfected with the NF-kB activity reporter with or without cotransfection with indicated siRNAs or cDNAs were subjected to Dual-Luciferase Reporter Assay (Promega) after desired treatment.
Anchorage-independent cell growth
Cells (5 Â 10 4 ) were seeded in 0.3% cell agar layer, which was on top of 0.6% base agar layer in 12-well culture plates. Cells were then incubated for a further 30 days at 37 C and 5% CO 2 . Cell colony formation was then examined under a light microscope.
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation were carried out as described previously (30, 31) . In brief, equal amounts of protein extracts were resolved by SDS-PAGE and analyzed by Western blot. For immunoprecipitation, extracts were mixed and precipitated with antibody and protein A/G Agarose beads by incubation at 4 C. The bound proteins were removed by boiling in SDS buffer and resolved in SDS-PAGE gels for immunoblotting analysis.
Quantitative PCR analysis
Quantitative PCR (qPCR) was carried out as described before (30) . Briefly, the reaction was carried out for 40 cycles: 95 C for 15 seconds; 60 C for 1 minute. The relative abundance of mRNA expression of a control sample was arbitrarily designated as 1. Primers used were listed in Supplementary Experimental Procedures.
Small interference RNA
The siRNAs were purchased from GenePharma. Transfection of siRNAs was carried out in Opti-MEM medium (Invitrogen) using Lipofectamine reagent (Invitrogen) according to the manufacturer's transfection protocol (27) .
Short hairpin RNA
The human RIP1 shRNA Kit (TG320591), human PTEN shRNA Kit (TG320498), and scramble shRNA Kit (TG300130), in which shRNA constructs are in retroviral GFP vector (pGFP-VRS), were purchased from Origene and were used according to the manufacturer's protocols.
Plasmid vectors and transfection
The lentivirus-based inducible gene expression system (Vira-Power HiPerform T-REx Gateway Vector Kit) was purchased from Invitrogen. The pCMV-Myc-RIP1 construct was from Origene. A mutant RIP1 construct containing four silent mutations within the RIP1 shRNA1 target sequence was also cloned into the pCMV-Myc vector. The kinase dead RIP1 (RIP1-K45A) construct was from Dr. Zheng Gang Liu (National Cancer Institute, Bethesda). The pCR-cFLIP construct was from Dr. H Nakano (Juntendo University School of Medicine, Tokyo, Japan). Plasmids were transfected as described previously (27) .
Melanoma xenograft mouse model
Studies on melanoma xenografts were approved by the Animal Research Ethics Committee of Shanxi Cancer Hospital of China and were carried out as previously described (27) . Briefly, cells (1 Â 10 7 ) were injected s.c. into each flank of male athymic nude mice (Model Animal Research Centre of Nanjing University, China). Tumor growth was measured every 2 days using a caliper. Mice were sacrificed, and tumors were weighed at 30 days after tumour cell transplantation.
Statistical analysis
The statistical analysis was performed using JMP Statistics Made Visual software. The Student t test or Kruskal-Wallis test was used to assess differences between different groups. A P value less than 0.05 was considered statistically significant.
Results
RIP1 is frequently upregulated in human melanoma
We examined the expression of RIP1 by use of IHC in tissue microarrays constructed from 100 FFPE melanocytic tumors ( Supplementary Table S1 ; ref. 27 ). The results revealed that RIP1 expression was frequently increased in melanomas compared with nevi ( Fig. 1A and B and Supplementary Table S1 ). However, there was no significant difference in RIP1 levels between thin and thick primary, or between primary and metastatic melanomas ( Fig. 1B ; Supplementary Fig. S1 and Supplementary Table S1 ), suggesting that RIP1 is upregulated at early stages in the pathogenesis of melanoma.
We also examined RIP1 expression in a panel of melanoma cell lines, which were generated from melanomas of different stages and had varying status of the most common mutations in BRAF (BRAF V600E ) and NRAS (NRAS Q61R ) (Fig. 1C ). RIP1 was also commonly expressed at increased levels in the melanoma cell lines irrespective of their origins and genetic backgrounds in comparison with cultured melanocytes [pooled melanocytes Tetracycline cancerres.aacrjournals.org Downloaded from from 3 different lines (HEMa-LP, HEMn-DP, and HEMn-MP) were used to simplify analysis as these melanocytes expressed similarly low levels of RIP1; Fig. 1C and Supplementary Fig. S2 ]. The elevated RIP1 expression was also evidenced in a panel of 21 fresh metastatic melanoma isolates by immunoblotting ( Fig. 1D ).
RIP1 promotes melanoma cell proliferation
We focused on examination of the functional significance of RIP1 upregulation in melanoma cells. Although RIP1 knockdown did not cause melanoma cell death, it inhibited cell proliferation as shown in BrdUrd incorporation and clonogenic assays ( Fig.  2A-C ). Introduction of a construct expressing shRNA-resistant RIP1 cDNA reversed the inhibitory effect ( Fig. 2D and E) , demonstrating the specificity of the RIP1 shRNA and consolidating the role of RIP1 in regulation of melanoma cell proliferation.
We introduced an RIP1-expressing construct into MM200 and IgR3 cells that expressed relatively low levels of endogenous RIP1 to establish sublines (MM200.RIP1 and IgR3.RIP1) conditionally expressing RIP1 in response to Tet (Fig. 2F ). Induction of RIP1 reduced cell viability by approximately 10%, which could be reversed by the general caspase inhibitor z-VAD-fmk, indicative of induction of apoptosis ( Supplementary Fig. S3A ; ref. 32 ). Nevertheless, the remaining cells with RIP1 overexpression acquired increased proliferation rates ( Fig. 2G ). Of note, the RIP1 kinase inhibitor Nec-1 did not affect cell death caused by RIP1 overexpression ( Supplementary Fig. S3A ), consistent with previous reports that introduction of a kinase domain-defective form of RIP1 induced cell death to the similar extent as overexpression of wild-type RIP1 (6, 20) . Indeed, introduction of a kinase-dead RIP1 mutant similarly reduced viability of MM200 and IgR3 cells ( Supplementary Fig. S3B ). Nevertheless, kinase-dead RIP1 retained the ability to promote melanoma cell proliferation irrespective of the presence of Nec-1 ( Fig. 2I ), indicating that RIP1-mediated promotion of melanoma cell proliferation is similarly independent of its kinase activity. In support, Nec-1 did not affect melanoma cell proliferation even in MM200 and IgR3 cells overexpressing RIP1 ( Supplementary Fig. S3C ).
RIP1 promotes melanoma cell proliferation through activation of NF-kB
As reported before, NF-kB was constitutively activated at high levels in melanoma cells compared with melanocytes (Supplementary Fig. S4; ref. 33 ). However, the levels of activation were reduced when RIP1 was knocked down (Fig. 3A and B) . Consistently, phosphorylation of IkBa at Serine 32/36 (p-IkBa S32/36) that is marked for degradation was decreased ( Fig. 3B; ref. 34 ). Introduction of the shRNA-resistant form of RIP1 reversed the inhibitory effect of RIP1 knockdown on activation of NF-kB ( Fig.   3A ), further verifying the role of RIP1 in NF-kB activation. Indeed, TAK1 and NEMO that are essential for RIP1-mediated NF-kB activation were coprecipitated with RIP1 in melanoma cells ( Fig.  3C; ref. 35 ). Moreover, RIP1 overexpression increased NF-kB activation in MM200 and IgR3 cells (Fig. 3D) .
The significance of NF-kB in RIP1-mediated promotion of melanoma cell proliferation was demonstrated by introduction of a nondegradable mutant of IkBa (IkBa-S32AS36A; ref. 29) , which inhibited melanoma cell proliferation even when RIP1 was overexpressed ( Fig. 3E and F) . Similarly, the NF-kB inhibitors PDTC and BAY-11-7082 also abolished RIP1 overexpressiontriggered enhancement in melanoma cell proliferation ( Fig. 3G ; ref. 29 ). These results indicate that NF-kB activation plays an important role in RIP1-mediated promotion of melanoma cell proliferation. This was further supported by the finding that RIP1 knockdown could not reduce melanoma cell proliferation when IkBa was co-knocked down, which caused NF-kB hyperactivation ( Fig. 3H-J) . Furthermore, the levels of NF-kB activity appeared positively associated with the levels of RIP1 expression in fresh metastatic melanoma isolates (Figs. 1D and 3K).
RIP1 modulates melanoma growth
To investigate whether elevated RIP1 contributes to melanocyte transformation, we introduced the RIP1-expressing construct into HEMn-MPmelanocytes (Fig.4A) .Alikeitseffectonmelanomacells, RIP1 overexpression reduced viability of melanocytes by approximately 10% in a caspase-dependent manner ( Supplementary  Fig. S5 ). Nevertheless, it increased the proliferation rate of the remainingcells.ThiswasassociatedwithincreasedNF-kBactivation as it could be reversed by the NF-kB inhibitor BAY-11-7082 ( Fig. 4A  and B ). Moreover, RIP1 overexpression triggered anchorage-independentgrowth comparable with that observed with knockdown of PTEN, which was used as a control ( Fig. 4C-E; ref. 27 ).
To examine whether elevated RIP1 affects melanoma growth in vivo, we transplanted Mel-RM cells with or without RIP1 stably knocked down into nu/nu mice (Fig. 4F ). Deficiency in RIP1 caused retardation of tumor growth ( Fig. 4G and H) , which was associated with increased expression of IkBa and reduction in its phosphorylation (p-IkBa S32/36; Fig. 4I ). The role of RIP1 in promoting melanoma tumorigenesis was confirmed by transplanting MM200 cells stably overexpressing RIP1 into nu/nu mice (Fig. 4J ). This demonstrated that RIP1 overexpression increased NF-kB activation and promoted melanoma growth in vivo ( Fig. 4K-M) .
Posttranslational modification is critical for upregulation of RIP1 in melanoma cells
In contrast with the common increase in the RIP1 protein, there were wide variations in RIP1 mRNA levels in melanoma cell lines Figure 3 . NF-kB plays a role in RIP1-mediated promotion of melanoma cell proliferation. A, Mel-RM and ME4405 cells with RIP1 stably knocked down (Mel-RM.shRIP1 and ME4405.shRIP1 cells, respectively) transfected with shRNA-resistant RIP1 cDNA (Mut-RIP1 cDNA) were subjected to NF-kB reporter assays (n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. B, Mel-RM.shRIP1 and ME4405.shRIP1 cells were subjected to Western blotting. C, immunoprecipitation analysis showing association of TAK1 and NEMO with RIP1 in Mel-RM and ME4405 cells. D, cells stably transduced with Tet.Ctrl or Tet.RIP1 treated with Tet (1 mg/mL) were subjected to NF-kB reporter assays (n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. E and F, cells stably transduced with Tet.RIP1 were transiently transfected with IkBa-S32AS36A constructs. Cell were treated with Tet (1 mg/mL) and subjected to Western blotting (E) or BrdUrd incorporation assays (F; n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. G, cells stably transduced with Tet.RIP1 pretreated with the NF-kB inhibitor PDTC (1 mmol/L) or BAY-11-7082 (1 mmol/L) for 2 hours were treated with Tet (1 mg/mL) for another 72 hours followed by BrdUrd incorporation assays (n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. H-J, Mel-RM.shRIP1 and ME4405.shRIP1 cells transiently transfected with IkBa siRNA were subjected to Western blotting (H), NF-kB reporter (I), or BrdUrd incorporation assays (J; n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. K, regression analysis of the relationship between RIP1 levels as shown in Fig. 1D and NF-kB activity as measured by NF-kB reporter assays in 21 fresh melanoma isolates (n ¼ 3, mean AE SEM). and fresh isolates ( Fig. 5A and Supplementary Fig. S6A ). In particular, some melanoma cell lines expressed even reduced levels of the RIP1 mRNA relative to melanocytes (Fig. 5A ). qPCR analysis of genomic DNA showed that one of 11 melanoma cell lines and one of 7 fresh melanoma isolates had copy-number gain of the RIP1 gene ( Fig. 5B and Supplementary Fig. S6B ), in keeping with the TCGA dataset showing that RIP1 copy-number gain occurred in 5.3% (20/375) of melanomas (www.cbioportal. org/public-portal). These data suggest that although DNA copy-number gain contributes to upregulation of RIP1 in some melanomas, posttranscriptional upregulation is a more commonly involved mechanism. In support, the turnover rates of the RIP1 mRNA remained comparable between melanoma and melanocyte cell lines regardless of its expression levels ( Supplementary  Fig. S7 ). Furthermore, the turnover rates of the RIP1 protein were prolonged in melanoma cell lines expressing higher levels of the protein (Fig. 5C and D) . We examined the ubiquitination status of RIP1 in Mel-RM and ME4405 cells that expressed relatively high levels of the protein. RIP1 was constitutively ubiquitinated with K63-linked ubiquitin chains as determined using an antibody specifically directed to k63-linked ubiquitin ( Fig. 5E ), suggesting that ubiquitination of RIP1 by cIAP1 and cIAP2 plays a role in its upregulation in melanoma cells. This was supported by the physical association of cIAP1 and cIAP2 with RIP1 as shown by coimmunoprecipitation assays (Fig. 5F) , and was further consolidated by downregulation of RIP1 when cIAP1, and to a lesser extent, cIAP2, was reduced by the Smac mimetic SM406, or when cIAP1 or cIAP2 was knocked down (Fig. 5G-I) .
Autocrine TNFa contributes to upregulation of RIP1 in melanoma cells
In keeping with previous reports (36), the TNFa transcript was readily detected in melanoma cells (Fig. 6A) . Moreover, the TNFa protein was found in supernatants of melanoma cell cultures, although the levels varied widely among melanoma cell lines (Fig. 6B ). Nevertheless, melanoma cells expressed in general higher levels of TNFa mRNA than melanocytes (Fig.  6A) . Similarly, melanoma cell culture media contained increased levels of its protein compared with melanocyte cell culture media (Fig. 6B) . Strikingly, the addition of a blocking antibody against TNFa in melanoma cell cultures caused reduction in RIP1 ubiquitination and expression and reduced the amount of cIAP1 and cIAP2 coprecipitated with RIP1 ( Fig.  6C-E ), suggesting that autocrine TNFa is responsible, at least in part, for upregulation of RIP1 through regulating cIAP-mediated RIP1 ubiquitination. Indeed, TNFaR1 knockdown also triggered reduction in RIP1 ubiquitination and expression and reduced the amount of cIAP1 and cIAP2 coprecipitated with RIP1 ( Fig. 6F-H) . Furthermore, the TNFa blocking antibody or TNFaR1 knockdown reduced NF-kB activation and decreased proliferation, albeit moderately, in melanoma cells, which could be abolished by RIP1 overexpression (Fig. 6I and J and Supplementary Fig. S8 ).
RIP1 protects melanoma cells from TNFa-induced apoptosis
Although RIP1 knockdown did not impinge on cell viability, it conferred sensitivity of a proportion of melanoma cells to apoptosis induced by recombinant TNFa (Fig. 7A ). This suggests that endogenous RIP1 plays a role in protecting melanoma cells from the toxicity of TNFa. Treatment with Nec-1 did not have a similar sensitizing effect (Fig. 7B) , indicating that RIP1 protects melanoma cells independently of its kinase activity.
We tested whether TNFa-induced apoptosis in RIP1 knockdown melanoma cells could be inhibited by cFLIP overexpression. As shown in Fig. 7C and D, RIP1 knockdown did not sensitize Mel-RM cells stably overexpressing cFLIP to TNFainduced apoptosis, suggesting that RIP1 inhibits TNFa-triggered cFLIP-inhibitable apoptosis in melanoma cells. Indeed, the levels of cFLIP are reduced in melanoma cells with RIP1 knocked down (Fig. 7E ). Co-knockdown of IkBa reversed RIP1 knockdownmediated reduction in cFLIP and enhancement in TNFa-induced killing (Fig. 7E and F) , indicating that RIP1 protects melanoma cells from apoptosis induced by TNFa through activation of NF-kB.
Discussion
Although RIP1 can mediate both cell survival and death signaling, many studies in recent years focused on its role in induction of apoptosis and programmed necrosis by various cellular stresses (6, 7, 20, 32) . Indeed, similar to our finding that introduction of exogenous RIP1 triggers apoptosis in a proportion of melanoma cells and melanocytes, RIP1 overexpression has been shown to cause apoptotic cell death in many other cell types (32) . These observations suggest that RIP1 may function primarily as an antisurvival protein and contribute to tumor suppression. However, we found in this study that RIP1 expression was frequently upregulated in melanoma cells, pointing to a role of RIP1 in favoring the pathogenesis of melanoma, and indicating that the expression of RIP1 must be under tight control so that its cellular level remains constantly below a threshold to ensure avoidance of apoptosis. Nevertheless, how RIP1 at high levels induces apoptosis in a selective population of melanoma cells and melanocytes remains unknown. This does not require the kinase activity of RIP1, as neither Nec-1 nor the kinase-dead mutant of RIP1 impinged on cell death. The death domain (DD) of RIP1 allows it to interact with other DD-containing proteins including FADD (6, 20) , which can in turn recruit caspase-8. It is conceivable that RIP1 at high concentrations may trigger proximity-driven dimerization of caspase-8, thus leading to its activation and apoptosis (6, 8) . On the other hand, cells that can survive RIP1 overexpression may possess intrinsic or acquired mechanisms that antagonize activation of caspase-8, thus protecting against apoptosis.
An important finding of this study is that RIP1 promotes melanoma cell proliferation and enhances melanoma growth. However, in contrast with previous reports in other types of cells (35, 37) , inhibition of p53 does not appear to play a major role in RIP1-mediated proliferation of melanoma cells, as knockdown of RIP1 similarly inhibited cell proliferation in p53-null melanoma cells (ME4405 cells; ref. 38 ). In addition, RIP1 knockdown does not affect p53 expression in melanoma cells (35, 37) . Moreover, RIP1 knockdown did not affect the expression of peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1a) that has been recently shown to play a role in RIP1-mediated suppression of p53 though regulating mitochondrial oxidative phosphorylation and glycolysis in lung cancer cells (data not shown; ref. 39). Although the mechanism responsible for this cell type-dependent involvement of p53 in RIP1-mediated regulation of cell proliferation remains to be addressed, it is known that wildtype p53 is often expressed at high levels but fails to exert an effective tumor suppressive role in melanoma cells (38) . NF-kB is not involved in RIP1-mediated promotion of cell proliferation in some types of cells (5, 39) . However, we found that NF-kB activation was critical for RIP1 to promote melanoma cell proliferation. This was demonstrated by (i) RIP1 knockdown resulted in decreased NF-kB activation, whereas melanoma cells that survived RIP1 overexpression displayed increased NF-kB activation; (ii) TAK1 and NEMO were physically associated with RIP1; (iii) inhibition of NF-kB activation abolished enhancement in proliferation of melanoma cells overexpressing RIP; and (iv), hyperactivation of NF-kB eliminated RIP1 knockdown-mediated inhibition of cell proliferation. The mechanisms regulating cell type-dependent involvement of NF-kB remain to be clarified. Regardless, our results indicate that RIP1 is responsible, at least in part, for constitutive NF-kB activation that is commonly found at high levels in melanoma cells (29, 40) .
Although RIP1 was expressed at elevated levels in melanoma cells, its mRNA levels varied widely in melanoma cells, and in some cases, were even lower than the levels in melanocytes. These findings promoted us to examine posttranscriptional mechanisms responsible for RIP1 upregulation. Indeed, RIP1 was constitutively polyubiquitinated with K63-linked ubiquitin chains, which is known to stabilize the protein (8) (9) (10) (11) 13) . Consistent with the established role of cIAPs in K63-linked polyubiquitination of RIP1 (9, 10), cIAP1 and cIAP2 were physically associated with RIP1. Because cIAP1s are transcriptional targets of NF-kB and RIP1 contributes to constitutive activation of NF-kB (9, 22, 41) , it seems that a dynamic positive feedback loop of NF-kB-cIAPs-RIP1 maintains the high levels of RIP1 expression and NF-kB activation in melanoma cells (Figs. 1A-D and 3A). Figure 5 . Posttranslational modification contributes to upregulation of RIP1 in melanoma cells. A, total RNAs from melanocytes and melanoma cells were subjected to qPCR analysis (n ¼ 3, mean AE SEM). B, genomic DNA from melanocytes and melanoma cells were subjected to qPCR analysis (n ¼ 3, mean AE SEM). C, whole-cell lysates from melanoma cells treated with cycloheximide (CHX; 1 mg/mL) were subjected to Western blotting. D, quantitation of the Western blot bands as shown in C. E and F, RIP1 immunoprecipitates from whole-cell lysates of cells were subjected to Western blotting. G, cells treated with the SM406 (1 mmol/L) for 48 hours were subjected to Western blotting. H and I, cells transfected with cIAP1 (H) or cIAP2 (I) siRNA were subjected to Western blotting. Melanoma cells have long been known to secrete TNFa, which promotes melanoma progression (42) . Consistent with this, we found that autocrine TNFa played an important role in sustaining the NF-kB-cIAPs-RIP1-positive feedback loop in melanoma cells (Fig. 6 ). Because the production of TNFa is transcriptionally regulated by NF-kB (42), it appears that TNFa is an essential built-in apparatus of the NF-kB-cIAPs-RIP1 feedback loop, and plays a driving role in activation of these intracellular components. These results suggest that autocrine TNFa may be involved in intrinsic resistance of melanoma cells to treatment. Indeed, RIP1 protects melanoma cells from TNFa-induced apoptosis. A, cells with RIP1 stably knocked down treated with TNFa (30 ng/mL) for 48 hours were subjected to CellTiter-Glo assays (n ¼ 3, mean AE SEM). Ã , P < 0.05, Student t test. B, cells pretreated with Nec-1 (30 mmol/L) for 1 hour were treated with TNFa (30 ng/mL) for further 48 hours followed by CellTiter-Glo assays (n ¼ 3, mean AE SEM). C and D, cells with RIP1 stably knocked down transduced with cFLIP cDNA (Mel-RM.cFLIP) were subjected to Western blotting (C) or treatment with TNFa (30 ng/mL) followed by CellTiter-Glo assays (D; n ¼ 3, mean AE SEM).
TNFa receptor activation contributes to resistance of melanoma to therapeutic agents such as BRAF inhibitors through activation of NF-kB (43) . Autocrine TNFa also contributes to cell proliferation and resistance to treatment in some other types of cancers (44) .
In addition to autocrine TNFa, cancer cells are commonly exposed to microenvironments characterized by chronic inflammation associated with high levels of TNFa production (45) . Circumvention of the cell death-inducing potential is essential for cancer cells to evade this detrimental effect of TNFa. We found that, despite its established role in TNFa-induced cell death when cIAPs are inhibited (20, 32) , RIP1 played a role in protection of melanoma cells from apoptosis induced by TNFa through NF-kB activation and subsequent upregulation of cFLIP. Thus, cFLIP is a major effector of the NF-kB-cIAPs-RIP1 feedback loop that protects melanoma cells from apoptosis induced by TNFa. Of note, although TNFa plus Smac mimetic induces apoptosis in many types of cells including melanoma cells (6, 46) , we did not observe significant apoptosis in all but one melanoma cell line treated with the combination of TNFa and the Smac mimetic SM406. This is conceivably due to cell line-dependent effects of the treatment.
The role of RIP1 as an oncogenic regulator in the pathogenesis of melanoma is consolidated by the finding that RIP1 overexpression promoted proliferation and triggered anchorage-independent growth of melanocytes. Indeed, the significant increase in RIP1 expression in primary melanomas compared with nevi indicates that RIP1 upregulation is an early event during melanomagenesis. Importantly, RIP1 upregulation is not associated with oncogenic activation of NRAS or BRAF, suggesting that it may cooperate with oncogenic mutations in NRAS or BRAF to promote the pathogenesis of melanoma, and that inhibition of the oncogenic activity of RIP1 may negatively regulate melanoma growth irrespective of mutations in NRAS/BRAF, which often underlies resistance of melanoma to treatment (47) . Our finding that RIP1 promotes melanoma cell proliferation through NF-kB points to the possibility of targeting the intermediate domain of RIP1 that is required for NF-kB activation as a novel approach in the treatment of melanoma (5, 48) . However, this has to be cautiously evaluated, as RIP1 is known to mediate cancer cell death induced by various agents (5) (6) (7) . Furthermore, inhibitors that target the intermediate domain of RIP1 have to be carefully designed so that they do not impinge on the kinase activity of RIP1 as do currently available RIP inhibitors such as Nec-1 that inhibit RIP1mediated cell death (8, 49) .
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